Voyager Therapeutics EV/EBIT VYGR

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 0.6×; Dec 2024
6-year median: 1.9×
6-year range: 0.0× to 10.2×
Peer median: 7.8×

Voyager Therapeutics has no meaningful EV/EBIT today: it made an operating loss of $117.2M over the last twelve months.

It was last meaningful in Dec 2024, at 0.6×.

On the days it had one over the last 6 years, its median was 1.9×, from 0.0× in Mar 2021 to 10.2× in Oct 2021.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	0.6×	0.6×	3.1×
2023	2.7×	0.1×	3.2×
2022	n/m a value too high to mean anything
2021	0.1×	0.0×	10.2×
2020	1.8×	1.8×	3.5×

Against its peers

Companies in Healthcare nearest Voyager Therapeutics' size, closest first, today.

Company	EV/EBIT
VYGRVoyager Therapeutics	n/m
KEQUKewaunee Scientific	7.2×
ICCCImmucell	14.2×
LFVNLifevantage	9.6×
SPROSpero Therapeutics	2.1×
PDEXPro DEX	16.0×
APTAlpha Pro Tech	8.2×
PLXProtalix BioTherapeutics	7.5×
NATRNatures Sunshine Products	5.2×
ELMDElectromed	14.4×
UTMDUtah Medical Products	6.0×
Peer median	7.8×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Voyager Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.